BioSpace

Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.

Por BioSpace

1 minuto de lectura
Compartir
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas